According to the company, the proteins are CGEN M-3, a soluble kinase receptor with potential applications in cancer, and CGEN P-4, a peptide that may be useful in the areas of obesity and eating disorders.
The proteins, said Compugen, were initially predicted in-silico and are now being evaluated in the company's molecular biology labs.